2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Owing to recent advances in early reperfusion strategies, pharmacological therapy,
standardized care, and the identification of vulnerable patient subsets, the prognosis of …

Objectives The aim of this study was to compare short dual antiplatelet therapy (DAPT) and
de-escalation in a network meta-analysis using standard DAPT as common comparator …

Aims Dual-antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is the
standard treatment for patients with acute coronary syndrome (ACS) undergoing …

Background: The benefit of dual antiplatelet therapy (DAPT) for reducing ischemic events is
greatest in the early period of acute coronary syndrome, and recent randomized controlled …

Dual antiplatelet therapy with aspirin and the oral P2Y12 inhibitor clopidogrel as the
cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing …

Aim Optimal dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary
intervention (PCI) for acute coronary syndrome (ACS) intends to balance ischemic and …

BACKGROUND: Short-term (≤ 6 months) dual antiplatelet therapy (DAPT) and DAPT de-
escalation become attractive for patients with acute coronary syndrome. METHODS: A …

Background Guideline-recommended dual antiplatelet therapy (DAPT; aspirin plus
prasugrel/ticagrelor) for 12 months in acute coronary syndrome (ACS) patients increases …

The thrombosis-related diseases are one of the leading causes of illness and death in the
general population, and despite significant improvements in long-term survival due to …